Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Liabilities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 64.94% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 64.94% decrease, with the full-year FY2025 number at $1.8 million, down 64.94% from a year prior.
  • Other Non-Current Liabilities was $1.8 million for Q4 2025 at Akebia Therapeutics, down from $5.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $83.1 million in Q1 2022 to a low of $760000.0 in Q4 2022.
  • A 5-year average of $25.2 million and a median of $6.7 million in 2024 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: soared 3789.1% in 2021, then plummeted 79.83% in 2023.
  • Akebia Therapeutics' Other Non-Current Liabilities stood at $1.8 million in 2021, then plummeted by 58.24% to $760000.0 in 2022, then skyrocketed by 1069.08% to $8.9 million in 2023, then crashed by 41.47% to $5.2 million in 2024, then crashed by 64.94% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Non-Current Liabilities are $1.8 million (Q4 2025), $5.0 million (Q3 2025), and $5.4 million (Q2 2025).